{
    "clinical_study": {
        "@rank": "147817", 
        "arm_group": [
            {
                "arm_group_label": "GS-7340 8mg", 
                "arm_group_type": "Experimental", 
                "description": "After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days."
            }, 
            {
                "arm_group_label": "GS-7340 25mg", 
                "arm_group_type": "Experimental", 
                "description": "After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days."
            }, 
            {
                "arm_group_label": "GS-7340 40mg", 
                "arm_group_type": "Experimental", 
                "description": "After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days."
            }, 
            {
                "arm_group_label": "GS-7340 120mg", 
                "arm_group_type": "Experimental", 
                "description": "After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days."
            }, 
            {
                "arm_group_label": "Tenofovir disoproxil fumarate 300mg", 
                "arm_group_type": "Experimental", 
                "description": "After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label study evaluating multiple doses of GS-7340 versus Tenofovir disoproxil\n      fumarate (TDF)."
        }, 
        "brief_title": "A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, open-label, active-controlled study whose primary objective is to\n      evaluate the safety and efficacy of several doses of GS-7340. This study will evaluate the\n      safety, viral kinetics, and antiviral activity of 4 different doses of GS-7340 over 28 days\n      of therapy. In addition, the study will evaluate the antiviral activity of an optimal dose\n      of GS-7340 versus 300mg Tenofovir disoproxil fumarate (TDF) over 28 days of therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be between 18 and 65 years of age\n\n          -  Must have Screening plasma HBV DNA \u2265 2x10^3 IU/mL\n\n          -  Must have chronic HBV infection for at least 6 months\n\n          -  Must have estimated creatinine clearance (CLCr) \u2265 70 mL/min\n\n          -  Not pregnant or nursing\n\n          -  Women must be of non-childbearing potential OR of childbearing potential with\n             confirmed negative pregnancy tests\n\n          -  Consistent and correct use of recommended methods of birth control for men and women\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating subjects\n\n          -  Receipt of anti-HBV nucleoside/nucleotide therapy. Subjects who have failed prior\n             Interferon treatment, greater than 6 months prior to screening, are permitted to\n             participate in the study screening\n\n          -  Known co-infection with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV)\n\n          -  Presence of autoimmune disorders\n\n          -  History of liver disease other than Hepatitis B\n\n          -  History of Gilbert's Disease\n\n          -  Any sign of decompensated liver disease\n\n          -  Known or suspected cirrhosis\n\n          -  Evidence of hepatocellular carcinoma\n\n          -  Presence or history of cardiovascular disease, cardiomyopathy, and/or cardiac\n             conduction abnormalities\n\n          -  Electrolyte abnormalities\n\n          -  History of treatment that permanently alters the gastric condition\n\n          -  Alcohol or substance abuse\n\n          -  History of bleeding diathesis\n\n          -  Significant bone disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671787", 
            "org_study_id": "GS-US-320-0101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "GS-7340 8mg", 
                    "GS-7340 25mg", 
                    "GS-7340 40mg", 
                    "GS-7340 120mg"
                ], 
                "description": "Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.", 
                "intervention_name": "GS-7340", 
                "intervention_type": "Drug", 
                "other_name": "GS-7340"
            }, 
            {
                "arm_group_label": "Tenofovir disoproxil fumarate 300mg", 
                "description": "Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy", 
                "intervention_name": "Tenofovir disoproxil fumarate", 
                "intervention_type": "Drug", 
                "other_name": "Viread"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tenofovir", 
                "Tenofovir disoproxil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Hepatitis B", 
            "HBV", 
            "GS-7340", 
            "TDF", 
            "Tenofovir disoproxil fumarate", 
            "Gilead", 
            "Viread"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92105"
                    }, 
                    "name": "Research and Education Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland Institute of Human Virology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Health System"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine - St. Luke's Episcopal Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melborne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "03168"
                    }, 
                    "name": "Monash Medical Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3084"
                    }, 
                    "name": "Austin Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3004"
                    }, 
                    "name": "Alfred Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nedlands", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6009"
                    }, 
                    "name": "Linear Clinical Research Ltd"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V6Z2C9"
                    }, 
                    "name": "Downtown Infectious Diseases Clinic (University of British Columbia)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H8L6"
                    }, 
                    "name": "The Ottawa Hospital, General Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2C4"
                    }, 
                    "name": "Toronto General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3P3P1"
                    }, 
                    "name": "Algorithme Pharma"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Romuald", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G6W 8H1"
                    }, 
                    "name": "Pro-recherche"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1042"
                    }, 
                    "name": "Auckland Clinical Studies"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "zip": "B152TH"
                    }, 
                    "name": "University Hospitals Birmingham NHS Foundation Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE5 9RS"
                    }, 
                    "name": "Institute of Liver Studies, King's College Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW1-2BU"
                    }, 
                    "name": "University College London Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "E1 1BB"
                    }, 
                    "name": "Grahame Hayton Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "zip": "NG7 2UH"
                    }, 
                    "name": "Nottingham University Hospitals NHS Trust - Queens Medical Centre"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada", 
                "New Zealand", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 1b Randomized, Open Label, Active-Controlled Study to Assess the Safety, Viral Kinetics, and Anti-HBV Activity of GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B (CHB) Infection", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "John Flaherty, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Australia: National Health and Medical Research Council", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "New Zealand: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Time-weighted average change from baseline through Week 4 (DAVG4) in serum HBV DNA (log10 IU/mL) for GS-7340 8-, 25-, 40 and 120-mg.", 
            "measure": "Change in serum hepatitis B virus (HBV) DNA", 
            "safety_issue": "No", 
            "time_frame": "Up to Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671787"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Comparing the short-term antiviral activity of GS-7340 with TDF 300mg. This is measured by time-weighted average change from baseline through Week 4 (DAVG4) in serum HBV DNA (log10 IU/mL) for TDF.", 
                "measure": "Change in HBV DNA for tenofovir disoproxil fumarate (TDF)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 4"
            }, 
            {
                "description": "Time weighted change from baseline to day 29 (DAVG4) in serum HBV DNA (log10 IU/mL)", 
                "measure": "Change in HBV DNA of GS-7340 through 28 days of therapy", 
                "safety_issue": "No", 
                "time_frame": "Up to week 4"
            }, 
            {
                "description": "GS-7340 and tenofovir (TFV) PK parameters in plasma will be calculated as applicable: Cmax, Tmax, Clast, Tlast, T1/2, \u03bbz, AUC0-t, AUC0-last, AUC0-\u221e, %AUCexp.\nPK samples are collected on:\nBaseline/Day 1: 0 (predose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose\nAdditional predose plasma samples will be collected on Days 2, 5, 8, 10, 15, 19, 22, and 29/End of Treatment.", 
                "measure": "Pharmacokinetics (PK) of GS-7340 and/or tenofovir (TVF) following single and multiple doses of GS-7340 and TDF", 
                "safety_issue": "No", 
                "time_frame": "Up to week 4"
            }, 
            {
                "description": "Safety and tolerability is measured by the incidence of adverse events and graded laboratory abnormalities", 
                "measure": "Safety and Tolerability of Therapy", 
                "safety_issue": "Yes", 
                "time_frame": "Up to week 4"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}